门德尔对肠道微生物群和慢性病的随机分析:对草药干预的含义
Xulei Hu1,2, Le Wang1, Chen Lin1
1The First Clinical Medical College of Anhui University of Chinese Medicine, Hefei, China.
Medicine
|November 8, 2025
概括
这项研究使用了门德尔的随机化来将特定的肠道微生物与慢性病 (CKD) 风险联系起来. 它还确定了潜在的中国草药 (CHM) 用于管理慢性病患者的肠道健康.
科学领域:
- 微生物学 微生物学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 肠-轴描述了肠道微生物群和功能之间的双向关系.
- 慢性病 (CKD) 是一个具有复杂潜在机制的全球健康问题.
- 了解肠道微生物群在CKD中的作用对于开发新型治疗策略至关重要.
研究的目的:
- 调查肠道微生物群组成与患慢性病 (CKD) 的风险之间的潜在因果关系.
- 确定可能调节肠道微生物群的候选中国草药 (CHM),以有效管理慢性病.
主要方法:
- 孟德尔随机化 (MR) 分析利用全基因组关联研究 (GWAS) 对肠道微生物群和CKD的总结统计数据.
- 作为主要MR分析的逆方差加权 (IVW) 方法,得到异质性和变性测试的支持.
- 基因映射,通路丰富分析和基于已识别的微生物协会预测潜在的CHM.
主要成果:
- 核磁共振分析揭示了六种特定的肠道微生物群,与CKD风险增加显著相关.
- 功能性丰富分析表明,肠-轴中免疫和炎症相关途径的参与.
- 一个候选人CHM的小组预测,符合传统中医的原则,通过加强生命能量 (Qi) 和消除病原体来治疗疾病.
结论:
- 特定的肠道微生物群种群可能在CKD的发展或进展中起因作用.
- 这些发现为开发针对性肠道微生物群干预CKD的干预提供了基础.
- 在这项研究中发现的候选CHM值得进一步研究,以确定它们在调节肠道微生物群的有效性,以治疗慢性病.
相关概念视频
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
178
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
178
01:28Chronic Kidney Disease III: Interprofessional Care
331
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
331
01:25Chronic Kidney Disease I: Introduction
552
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
552
01:24Chronic Kidney Disease II: Clinical Manifestations
537
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
537
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
226
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
226